Recurrent Glioblastoma Multiforme Treatment Market, by Treatment (Oral Medication, Radiosensitizers, Nitrosoureas Drugs, and Chemotherapy ), by Type (Grade II or Grade III, Grade IV, and Others), and by Region (North America, Latin America, Europe, Asia P

Recurrent Glioblastoma Multiforme Treatment Market, by Treatment (Oral Medication, Radiosensitizers, Nitrosoureas Drugs, and Chemotherapy ), by Type (Grade II or Grade III, Grade IV, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Glioblastoma multiforme or GBM is an aggressive and the most common form of brain cancer that involves glial cells. Gliomas are rapidly developing tumors that develop from the star-shaped glial cells present in the spinal cord or brain. Recurrent glioblastoma multiforme is a possibility of reoccurrence of GBM after tumor surgery. This is because it is difficult to wholly remove the tumor during surgery and there is always a possibility that after a period of remission, cancer might recur. The symptoms of GBM include constant headaches, seizures, vomiting, difficulty in speaking, and double or blurred vision.
Market Dynamics
The rising incidence of brain cancers is expected to drive the recurrent glioblastoma multiforme treatment market growth over the forecast period. Although, researchers believe that egentic mutations may cause this disease, symptoms include seizures, change in mood, loss of appetite, double or blurred vision, change in ability to think and difficulty in speech. According to the statistics provided by the World Health Organization (WHO), each year, around 5 million people are diagnosed with epilepsy across the globe.
Moreover, tuberous sclerosis, neurofibromatosis, von-hippel-lindau disease, turcot syndrome, and Li-fraumeni syndrome are some of the genetic disorders related to the increasing prevalence of gliomas, which is expected to fuel the market growth during the forecast period.
Furthermore, key players in the market are increasingly investing in research & development to develop, create, and commercialize novel drugs, which is expected to create lucrative growth opportunities for the global recurrent glioblastoma multiforme treatment market in the near future. However, lack of effective therapies and the inability of drugs to effectively prevent tumor reoccurrence are predicted to restrict the market growth over the forecast period.
Key features of the study:
This report provides in-depth analysis of the global recurrent glioblastoma multiforme treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global recurrent glioblastoma multiforme treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study include GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Cantex Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc.
Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global recurrent glioblastoma multiforme treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for recurrent glioblastoma multiforme treatment market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Recurrent Glioblastoma Multiforme Treatment Market, By Treatment:
Oral Medications
Radiosensitizers
Nitrosoureas Drugs
Chemotherapy
Global Recurrent Glioblastoma Multiforme Treatment Market, By Type:
Grade II or Grade III
Grade IV
Others
Global Recurrent Glioblastoma Multiforme Treatment Market, By Region:
North America
By Country:
U.S.
Canada
By Treatment:
Oral Medications
Radiosensitizers
Nitrosoureas Drugs
Chemotherapy
By Type:
Grade II or Grade III
Grade IV
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Treatment:
Oral Medications
Radiosensitizers
Nitrosoureas Drugs
Chemotherapy
By Type:
Grade II or Grade III
Grade IV
Others
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Treatment:
Oral Medications
Radiosensitizers
Nitrosoureas Drugs
Chemotherapy
By Type:
Grade II or Grade III
Grade IV
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Treatment:
Oral Medications
Radiosensitizers
Nitrosoureas Drugs
Chemotherapy
By Type:
Grade II or Grade III
Grade IV
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Treatment:
Oral Medications
Radiosensitizers
Nitrosoureas Drugs
Chemotherapy
By Type:
Grade II or Grade III
Grade IV
Others
Africa
By Region:
North Africa
Central Africa
South Africa
By Treatment:
Oral Medications
Radiosensitizers
Nitrosoureas Drugs
Chemotherapy
By Type:
Grade II or Grade III
Grade IV
Others
Company Profiles
GlaxoSmithKline, Plc.
Company Overview
Treatment Portfolio
Financial Performance
Recent Highlights
Strategies
Astrazeneca
F. Hoffman-La Roche, Ltd.
Pfizer, Inc.
Merck & Co., Inc.
Vascular Biogeneics
AngioChem, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Boston Biomedical, Inc.
Cantex Pharmaceuticals, Inc.
Celldex Therapeutics, Inc.
Cavion LLC
Coherus BioSciences, Inc.
Eisai
Eli Lilly and Company
Cortice Biosciences, Inc.
EnGeneIC Ltd.
GenSpera, Inc.
ERC Belgium SA
Genzyme Corporation
ImmunoCellular Therapeutics, Ltd.
GW Pharmaceuticals Plc.
“*” marked represents similar segmentation in other categories in the respective section